Preferred Label : EGFR/HER2 Inhibitor ABT-101;
NCIt definition : An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR;
ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including
EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential
antineoplastic activity. Upon oral administration, EGFR/HER2 inhibitor ABT-101 targets,
binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents
EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth
in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family
is involved in key cellular functions, including cell growth and survival. EGFR and
HER2 alterations constitutively upregulate kinase activity.;
Molecule name : DBPR 112; DBPR-112; ABT-101; ABT 101;
NCI Metathesaurus CUI : CL554867;
Origin ID : C153427;
UMLS CUI : C5787202;
Semantic type(s)
- concept_is_in_subset
- has_target
